AIP4:Ruby proposes innovative technologies to effectively solve the most difficult and valuable membrane protein problems, integrating membrane protein-based disease diagnosis, biomarkers screening and target drugs discovering. AIP4:Ruby integrates AI technology, CaMPNets and iGEMDrug to provide membrane protein biomarker screening to target drug development services, which can shorten drug development time.

AIP4:Ruby integrates AI technology, CaMPNets and iGEMDrug to establish membrane protein-pathway-cancer-prognosis association for the most difficult and valuable membrane proteins problems. The innovation results have been successfully applied to the common diseases, such as fatty liver, smoking-induced diseases and diabetes, and found that JMY104 and JMY117 can be used as a new treatment strategy.

AIP4:Ruby links basic research, translational medicine and industry based on our core value. We obtained 3 US and Taiwan patents. CaMPNets applied for membrane proteins drug targets identification, iGEMDrug is a pipeline tool for structural drug design and key features identification. Besides, We have successfully found old drugs JMY104, JMY117 for some diseases. We can immediately provide services according to customer needs.